Markets:

Overview

News

Currencies

International

Treasuries

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NY:AMRX)

N/A UNCHANGED

Last Price Updated: 7:00 PM EST, Dec 26, 2023 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 Next >

21 Stocks Moving in Monday's Pre-Market Session ↗

April 18, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) shares rose 16.2% to $2.51 in pre-market trading. Mullen Automotive announced plans to begin construction for EV battery pack...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Booster Data In Kids, Regeneron's COVID-19 Therapy Decision Pushed, Protagonist's Rusfertide Breakthrough Tag Update And More ↗

April 14, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Amneal Scores Second US Biosimilars Approval With Alymsys In Oncology ↗

April 14, 2022

The FDA approved Amneal Pharmaceuticals Inc (NYSE: AMRX) Biologics License Application (BLA) for bevacizumab-maly, a biosimilar referencing Avastin. The product...

Via Benzinga

Amneal Achieves Second U.S. Biosimilars Approval with ALYMSYS® (bevacizumab-maly)

April 13, 2022

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Report First Quarter 2022 Results on May 4, 2022

April 07, 2022

From Amneal Pharmaceuticals, Inc.

Via Business Wire

The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight ↗

April 03, 2022

Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates ↗

April 01, 2022

Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with...

Via Benzinga

Amneal to Present Results From the Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 at the 2022 American Academy of Neurology Annual Meeting

March 24, 2022

From Amneal Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗

March 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Amneal Awarded Sub-License to Manufacture and Commercialize Generic Version of Co-Packaged Nirmatrelvir and Ritonavir in 95 Low- and Middle-Income Countries

March 17, 2022

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Pharmaceuticals's Return On Capital Employed Insights ↗

March 08, 2022

Amneal Pharmaceuticals (NYSE:AMRX) brought in sales totaling $536.90 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 235.83%, resulting...

Via Benzinga

Amneal Pharma's Q4 Earnings Fall Short Of Expectations, Sees FY22 Sales Growth Of 7% ↗

March 02, 2022

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q4 revenue of $537 million, an increase of 5% Y/Y, marginally missing the consensus of $537.35 million. The increase was...

Via Benzinga

The Daily Biotech Pulse: Karyopharm Flags Delay In Selinexor Label Expansion, Finch, Celyad Hit With Clinical Holds, Adagene Strikes R&D Collaboration With Sanofi ↗

March 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Karyopharm Says FDA Mandates Additional Study For Expanding Selinexor Label...

Via Benzinga

Recap: Amneal Pharmaceuticals Q4 Earnings ↗

March 02, 2022

Amneal Pharmaceuticals (NYSE:AMRX) reported its Q4 earnings results on Wednesday, March 2, 2022 at 06:00 AM. Here's what investors need to know about the announcement....

Via Benzinga

Amneal Pharmaceuticals's Earnings: A Preview ↗

March 01, 2022

Amneal Pharmaceuticals (NYSE:AMRX) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement....

Via Benzinga

Earnings Scheduled For March 2, 2022 ↗

March 02, 2022

Companies Reporting Before The Bell • SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million. •...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Amneal Expands Injectables Portfolio with 4 New Products

February 17, 2022

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Report Fourth Quarter and Full Year 2021 Results on March 2, 2022

February 04, 2022

From Amneal Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets ↗

January 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...

Via Benzinga

Amneal's $83M Saol Acquisition Deal Expands Its Neurology Presence Into Spasticity ↗

January 05, 2022

Amneal Pharmaceuticals Inc (NYSE: AMRX) has agreed to acquire Saol's Baclofen franchise, including Lioresal, Lyvispah, and a pipeline product under development for $...

Via Benzinga

Amneal Acquires Saol Therapeutics’ Baclofen Franchise

January 05, 2022

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Virtually Participate at the 40th Annual J.P. Morgan Healthcare Conference

December 21, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

December 17, 2021

Gainers GBS (NASDAQ:GBS

Via Benzinga

TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva ↗

December 08, 2021

TherapeuticsMD Inc (NASDAQ: TXMD) has settled the previously disclosed U.S. patent litigation for Bijuva with Amneal Pharmaceuticals Inc (NYSE: AMRX)....

Via Benzinga

Topics Intellectual Property

The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗

December 08, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-...

Via Benzinga

Topics Intellectual Property Lawsuit

Amneal Receives Approval for Difluprednate Ophthalmic Emulsion

November 19, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal to Virtually Participate at Upcoming Investor Conferences

November 12, 2021

From Amneal Pharmaceuticals, Inc.

Via Business Wire

Amneal Pharmaceuticals, inc (AMRX) Q3 2021 Earnings Call Transcript ↗

November 03, 2021

AMRX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

Amneal Posts Mixed Bag Q3 Earnings; Acquires Puniska To Bolster Injectable Business ↗

November 03, 2021

Amneal Pharmaceuticals Inc (NYSE: AMRX) reports Q3 revenue of $529 million, a marginal increase of 2% Y/Y, missing the consensus of $545.06 million. The increase was driven...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Amneal Pharmaceuticals, Inc. - Class A Common Stock (NY:AMRX)

All News about Amneal Pharmaceuticals, Inc. - Class A Common Stock

Starting at /week.